Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: No increased risk of bleeding

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 183-190

  Friedman, Richard J ^a   Kurth, Andreas A ^b   Clemens, Andreas ^c   Noack, Herbert ^c   Eriksson, Bengt I ^d   Caprini, Joseph A ^e  

^a Roper St Francis Healthcare   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

ASA; Bleeding; Dabigatran etexilate; Non steroidal anti inflammatory drugs; Oral

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

AGED; ARTHROPLASTY; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ASPIRIN; BENZIMIDAZOLES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PYRIDINES; RISK;

EID: 84863675086     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0589     Document Type: Article

References (26)

1. McNally MA, Mollan RAB. Venous thromboembolism and orthopaedic surgery. J Bone Joint Surg Br 1993; 75-B: 517-519.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 381-453S.
3. Turpie AG, Esmon C. Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011; 105: 586-596.
4. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
6. Dahl OE, Ögren M, Agnelli G, et al. Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Pathophysiol Haemost Thromb 2006; 35: 428-434.
7. Robinson CM, Christie J, Malcolm-Smith N. Nonsteroidal anti-inflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993; 8: 607-610.
8. Slappendel R, Weber EW, Benraad B, et al. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesthesiol 2002; 19: 829-831.
9. Fischer HB, Simanski CJ. A procedure-specific systematic review and consensus recommendations for analgesia after total hip replacement. Anaesthesia 2005; 60: 1189-1202.
10. Macie C, Forbes L, Foster GA, et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004; 125: 1616-1621.
11. Lotke PA, Lonner JH. Deep venous thrombosis prophylaxis: better living through chemistry - in opposition. J Arthroplasty 2005; 20 (Suppl 2): 15-17.
12. Guijarro R, Montes J, San Román C, et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011; 105: 610-615.
13. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidencebased clinical practice guidelines (8th Edition). Chest 2008; 133: 257-298S.
14. Pola E, Papaleo P, Santoliquido A, et al. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing hip arthroplasty. J Bone Joint Surg Am 2004; 86: 57-61.
15. Health Canada Drug Product Database. Available at: http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=79794. Accessed October 21, 2011.
16. European Medicines Agency. Pradaxa. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici nes/000829/human_med_000981.jsp&jsenabled=false. Accessed October 21, 2011.
17. Eriksson BI, Dahl OE, Rosencher N, et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
18. Eriksson BI, Dahl OE, Rosencher N, et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
19. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty. J Arthroplasty 2009; 24: 1-9.
20. The European Agency for the Evaluation of Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin e/2009/09/WC500003301.pdf. Accessed September 2, 2010.
21. Eriksson BI, Dahl OE, Büller HR, et al.; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
22. Hull RD, Pineo GF, Francis G, et al.; for the North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients. A double-blind, randomized comparison. Arch Intern Med 2000; 160: 2199-2207.
23. Turpie AGG, Bauer KA, Eriksson BI, et al; for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
24. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. Circulation 2011; 123: 2363-2372.
25. Dans AL, Connolly S, Bruckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial. Presented at the 33rd Congress of the European Society of Cardiology (ESC), Paris, 27-31 Aug 2011. Available at: http://www.escardio.org/congresses/esc-2011/congress-reports/Pages/709-S -RE-LY.aspx. Accessed April 25, 2012.
26. Astra Zeneca 2006. Astra Zeneca decides to withdraw Exanta TM. Available at: http://www.astrazeneca.com/media/latest-press-releases/2006/5217?itemId= 3891692. Accessed September 2, 2010.